- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03463239
Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora
Phase 1 Pilot Study of Bioengineered Penile Tissue Constructs in Subjects With Irreversibly Damaged Penile Corpora
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Damage to penile tissue due to infection, inflammation or trauma often leads to structural deformity that may result in loss of sexual function that can profoundly affect quality of life. Traumatic injuries in civilians and battlefield related injuries in soldiers often require reconstructive procedures to restore the anatomy and functionality of the penis. However, these procedures are often limited by poor availability of functionally intact penile tissue. Various penile reconstructive procedures, such as penile prostheses and autograft implantation have been attempted. While cosmetic appearance may be improved, restoration of spontaneous and natural erectile function is usually not achieved. This is often due to critical defect of the corpora cavernosa, which are responsible for erectile function. Recently, the concept of a tissue engineering-based therapy has been proposed for reconstructing damaged penile corporal tissue.
The primary objective of this Armed Forces Institute for Regeneration Medicine (AFIRM II) sponsored clinical trial is to evaluate the safety of autologous engineered corpora cavernosa + albuginea constructs for treatment of complex penile deformities. The proposed study design is a prospective non-randomized and uncontrolled, multi-center investigation. Autologous endothelial and smooth muscle cells obtained from enrolled participants' corpora cavernosa biopsy sample, will be culture expanded in vitro and used to seed decellularized corpora cavernosa + albuginea obtained from cadaveric-donors to create autologous bioengineered corpora cavernosa/albuginea constructs for repair of damaged penile tissues.
A total of ten male patients, referred for the treatment of damages of albuginea and/or corpora cavernosum without concurrent urethral injury will be recruited for this study. The estimated duration of the study for each subject following treatment is 36 months. The study team anticipates a duration of approximately 48 to 60 months to complete all enrollment and follow up. Enrolled participants will undergo a corporal tissue biopsy as an out-patient surgical procedure. Autologous corporal smooth muscle cells and corporal endothelial cells will be isolated and then seeded on cadaveric decellularized corporal bodies. Approximately 3-4 weeks later, the engineered construct including corporal tissue with attached tunica will be transplanted into the surgically prepared site of penile injury. Participants will be followed through 36 months post-implantation to monitor for safety.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Mary-Clare Day, RN, BSN
- Phone Number: 336-713-1343
- Email: mday@wakehealth.edu
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Institute for Regenerative Medicine
-
Contact:
- Mary-Clare Day, RN, BSN
- Phone Number: 336-713-1343
- Email: mday@wakehealth.edu
-
Sub-Investigator:
- James Yoo, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males aged 18-60 years.
- Acquired structural abnormalities of the corpora cavernosum secondary to trauma, infection, inflammation, or fibromatosis. These abnormalities will be diagnosed by clinical examination, and/or ultrasound, and/or computerized tomography.
- Stable abnormalities - at least 6 months with no pain or changes in deformity.
- At least one failed attempt at management by conventional approaches at least 6 months prior to enrollment
- Deformities less than 5 cm in length.
- Written informed consent obtained prior to participation in the study.
- Patients must be available for all follow up visits.
- Ability to speak English.
Exclusion Criteria:
- Presence of untreated or incompletely treated urinary tract infection at the time of biopsy.
- Uncontrolled bleeding disorder or patients with a platelet count less than 50,000, hemophilia or patients routinely receiving blood products for bleeding disorders.
- Serum creatinine > 2.0 mg/dl or evidence of progressive renal disease.
- ALT or AST value >1.5 times the upper limit of normal.
- Albumin < 3.0 g/dL.
- Serum direct bilirubin >0.3 mg/dL OR total bilirubin > 1.4 mg/dL
- BM I>40 kg/m2
- Uncontrolled diabetes with HbA1C>9%. (Subjects with controlled diabetes must be under care of diabetologist with treatment goals consistent with ADA criteria).
- Unstable cardiac disorders within the past 6 months including angina, abnormal ECG, history of cardiac arrest, surgery and/or other interventional procedure.
- Unstable pulmonary disorders within the past 6 months including dyspnea on exertion, chronic productive cough, pneumonia, hemoptysis, asthma requiring nebulized therapy.
- Active tuberculosis (TB) requiring treatment in the past 3 years. Subjects with a current positive (≥5 mm induration for high-risk subjects; otherwise ≥10 mm of induration) purified protein derivative (PPD) test are excluded unless they have completed a full course of treatment for latent TB and have a negative chest x-ray film at enrollment.
- Known to be colonization with either methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE), or gentamicin-resistant organisms.
- Immunocompromised subjects or subjects receiving immunosuppressive agents.
- Any history of alcohol and/or drug abuse.
- Documented history of, or positive result of HIV, Hepatitis B or C, or any infectious disease. External signs, sequelae, or positive serology of sexually transmitted disease (including HPV). Patients with a history of systemic conditions, including but not limited to HIV, diabetes and chronic liver disease (including Hepatitis B or C), that the Investigator believes may jeopardize the safety of the patient to participate in the study.
- Concurrent participation in any other clinical investigation during the period of this investigation. Patients who have been treated with any other investigational drug or participated in any investigational study within 30 days prior to enrollment in this study.
- Any circumstance in which the investigator deems participation in the study is not in the subject's best interest.
- Inability to participate in all necessary study activities due to physical or mental limitations.
- Inability or unwillingness to return for all required follow-up visits, for instance life expectancy < 1 year, or subject who knows they will be moving out of the country and unable to return for follow-up visits.
- Inability or unwillingness to sign informed consent.
- Patients requiring concomitant use of or treatment with immunosuppressive agents
- Patients with neurological disorders (e.g., multiple sclerosis, Parkinson's disease).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Autologous tissue engineered corpora
All subjects enrolled will undergo a corpora cavernosum biopsy.
Endothelial and smooth muscle cells will be isolated and expanded, then seeded onto a scaffold that will later be implanted into the subject.
|
penile tissue construct
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: monitored through 36 months post-treatment
|
rate of adverse events reported for each patient
|
monitored through 36 months post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with graft thrombosis or grant failures
Time Frame: monitored through 36 months post-treatment
|
lack of graft thrombosis or graft failure
|
monitored through 36 months post-treatment
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ryan P Terlecki, MD, Associate Professor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Congenital Abnormalities
- Pathological Conditions, Anatomical
- Nervous System Malformations
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Genital Diseases, Male
- Genital Diseases
- Inflammation
- Urologic Diseases
- Agenesis of Corpus Callosum
- Penile Diseases
- Urogenital Diseases
- Male Urogenital Diseases
Other Study ID Numbers
- IRB00046975
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urologic Diseases
-
University Hospital, GhentCompletedSurgery | Bladder Cancer | Urologic CancerBelgium
-
Chang Gung Memorial HospitalCompleted
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Chang Gung Memorial Hospital; Kaohsiung... and other collaboratorsRecruiting
-
Diskapi Yildirim Beyazit Education and Research...Unknown
-
Fundación Pública Andaluza para la gestión de la...RecruitingSurgery | Anesthesia | Urologic CancerSpain
-
IRCCS San RaffaeleRecruitingUrologic Diseases | Infertility | Urologic CancerItaly
-
Changhai HospitalUTC Therapeutics Inc.RecruitingCD70-positive Advanced Urologic NeoplasmsChina
-
Yonsei UniversityCompletedPediatric Urologic SurgeriesKorea, Republic of
-
Yonsei UniversityCompletedElective Urologic SurgeriesKorea, Republic of
-
Kasr El Aini HospitalUnknownUrologic Surgical ProceduresEgypt
Clinical Trials on Autologous tissue engineered corpora
-
Institut National de la Santé Et de la Recherche...Active, not recruitingEpidermolysis Bullosa Dystrophica, RecessiveFrance
-
First Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
A.A. Partners, LLCUnknown
-
University College, LondonMedical Research CouncilWithdrawnTracheal Stenosis | Laryngostenosis | Disorder of Upper Respiratory SystemUnited Kingdom
-
Wake Forest University Health SciencesUnited States Department of DefenseNot yet recruitingUrologic Diseases | Male Urogenital Diseases | Urethral Stricture | Urethral InjuryUnited States
-
Nationwide Children's HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsRecruitingHeart Diseases | Cardiovascular Diseases | Heart Defects, Congenital | Cardiovascular Abnormalities | HLH - Hypoplastic Left Heart Syndrome | DORV | DILV - Double Inlet Left Ventricle | Mitral Atresia | Tricuspid Atresia | Unbalanced AV Canal | Single-ventricleUnited States
-
University Hospital, Basel, SwitzerlandDeutsche Arthrose-HilfeCompletedDegenerative Lesion of Articular Cartilage of Knee | Cartilage LesionSwitzerland
-
Christopher BreuerGunze Limited; Doris Duke Charitable FoundationCompletedSingle Ventricle Cardiac AnomalyUnited States
-
Xijing HospitalUnknownBone Defect | Bone NonunionChina
-
Cytograft Tissue EngineeringCompleted